IRCT201604051556N87已完成未知
Citicoline as adjunctive treatment of negative symptoms in patients with schizophrenia: a double blind and placebo controlled trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •1-Diagnosis of Schizophrenia based on DSM-5 criteria; 2- Age between 18-60; 3-Chronic Schizophrenia- duration of the disorder more than 2 years; 4-Minimum score of 20 in negative sub score. 5-being stable on risperidone for the last 2 months. Exclusion criteria:1-Any serious medical or neurological problem; 2- IQ less than 70; 3- Substance dependence during the last 6 months(except for nicotine and caffeine); 4- Score on HDRS less than 14 5-receiving ECT during the last 3 months ; 6-Acute or chronic systemic diseases; 7- History of neurosurgery; 8- History of head trauma.
排除标准
- 未提供
研究者
相似试验
尚未招募
不适用
SE OF CITICOLINE DRUG IN TREATMENT OF AMBLYOPIA .OR LAZY EYE ASSOCIATED WITH IMPAIRED VISIOCTRI/2018/09/015653VISHAL DEV
进行中（未招募）
不适用
Citicoline in the treatment of acute ischemic stroke. An international randomized multicenter placebo-controlled study.Citicolina en el tratamiento del ictus isquémico agudo. Estudio internacional, multicéntrico. aleatorizado y controlado por placebo. - ICTUSEUCTR2005-004825-25-ESFerrer Internacional2,600
尚未招募
3 期
ROLE OF MEDICINE (CITICOLINE) IN ADULT PATIENTS OF LAZY EYE (AMBLYOPIA)CTRI/2022/01/039809DEEPANSH
已完成
2 期
Minocycline in the treatment of schizophreniaschizophrenia.schizophreniaIRCT201202241556N34Tehran University of Medical Sciences50
进行中（未招募）
1 期
Citicoline as supportive treatment in Parkinson's diseaseMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersParkinson's diseaseEUCTR2014-005562-30-ITPIAM FARMACEUTICI S.P.A.474